Intismeran cancer vaccine + Keytruda sustains 49% melanoma reduction after five years

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A combination of a cancer vaccine and a drug, both of which harness the immune system to attack cancer cells, has proven successful in cutting the risk of skin cancer recurrence and death by 49%, according to a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login